They are still researching new product lines though. Not many biomed companies ever produced a single cent of revenue until they get licensed or bought by big pharma. This is a pretty unique story and I think should not be valued based on their revenue alone. Of course we all want to see triple digit growth but I think the fact that they are doing revenue and has growth to it is a prove of concept already and only a matter of time before this gets widely adopted. Plenty of cash in the bank to see this cross to where it should be before the next CR too which is a big tick. All IMO
OSX Price at posting:
44.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)